Short answer
Cooper Companies (The) (COO) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Fiscal Q3 2026 results released September 9, 2026, covering the quarter ended July 31, 2026.
Cooper Companies (The) 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal Q3 2026 results released September 9, 2026, covering the quarter ended July 31, 2026
- Detailed financial performance and management commentary contained in Exhibit 99.1
- Earnings release excluded from Section 18 liability and filing incorporation absent specific reference
Item 8.01 · Other Events
- Strategic review completed, signaling no immediate major portfolio or strategic transaction announcement
- Increased share repurchase authorization, supporting capital returns and potentially reducing shares outstanding
- Press release dated September 9, 2026; substantive authorization details appear in Exhibit 99.2
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.066B, up 1% organically, with CooperSurgical growth offset by flat CooperVision sales
- Non-GAAP EPS $1.15, up 4%, while GAAP EPS $2.24 benefited from a $307.2M U.K. tax examination benefit
- Free cash flow $273.0M, up 66%, supporting $339.1M of buybacks and approximately 4.9M shares repurchased
- CooperVision channel inventory reduction pressures Q4, with guidance calling for organic growth of negative 2% to 0%
- FY2026 non-GAAP EPS guidance $4.51-$4.55 and revenue guidance $4.229B-$4.252B, while strategic review actions target shareholder value
Item EX-99.2 · Exhibit EX-99.2
- Strategic review completed, CooperSurgical retained after offers were deemed below shareholder value
- Share repurchase authorization increased from $2 billion to $3 billion, with $445 million repurchased in fiscal 2026
- Capital allocation shifts toward buybacks, CooperVision growth investments and CooperSurgical operational improvements
- Two independent healthcare executives added to the Board, strengthening oversight and shareholder alignment
- Initiatives target stronger sales execution, cost efficiency, logistics, direct shipping and accelerated contact-lens innovation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cooper Companies (The) 8-K filings
Get the next COO 8-K as it lands
Follow COO for push alerts, or ask the research agent what this filing means.